• 1
    Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 14881500.
  • 2
    Patel R and Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735739.
  • 3
    Johnson AH, Rossen RD, Butler WT. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: Identification of low levels of pre-formed antibodies in accelerated allograft rejection. Tissue Antigens 1972; 2: 215226.
  • 4
    Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004; 29: 4154.
  • 5
    Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 4349.
  • 6
    Appel JZ III, Hartwig MG, Cantu E III, Palmer SM, Reinsmoen NL, Davis RD. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006; 81: 10491057.
  • 7
    Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346351.
  • 8
    Akalin E, Ames S, Sehgal V et al. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 2005; 79: 742.
  • 9
    Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria – an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708714.
  • 10
    Vaidya S, Cooper TY, Avandsalehi J et al. Improved flow cytometric detection of HLA alloantibodies using pronase: Potential implications in renal transplantation. Transplantation 2001; 71: 422428.
  • 11
    Sumitran-Holgersson S, Wilczek HE, Holgersson J, Soderstrom K. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 74: 268277.
  • 12
    Sumitran-Karuppan S, Tyden G, Reinholt F, Berg U, Moller E. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997; 5: 321327.
  • 13
    Dragun D, Muller DN, Brasen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558569.
  • 14
    Zou Y, Heinemann FM, Grosse-Wilde H et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006; 67: 230237.
  • 15
    Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, Shih RN et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 22652272.
  • 16
    Piazza A, Poggi E, Ozzella G et al. Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: Alloantibody characterization by flow cytometric techniques. Transplantation 2006; 81: 12981305.
  • 17
    Adams AB, Pearson TC, Larsen CP. Heterologous immunity: An overlooked barrier to tolerance. Immunol Rev 2003; 196: 147160.
  • 18
    Karpinski M, Rush D, Jeffery J et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12: 28072814.
  • 19
    Noreen HJ, McKinley DM, Gillingham KJ, Matas AJ, Segall M. Positive remote crossmatch: Impact on short-term and long-term outcome in cadaver renal transplantation. Transplantation 2003; 75: 501505.
  • 20
    Gebel HM, Harris SB, Zibari G, Bray RA. Conundrums with flowPRA beads. Clin Transplant 2002; 16(Suppl 7): 2429.
  • 21
    Gloor JM, Degoey S, Ploeger N et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221227.
  • 22
    Taylor CJ, Smith SI, Morgan CH et al. Selective omission of the donor cross-match before renal transplantation: Efficacy, safety and effects on cold storage time. Transplantation 2000; 69: 719723.
  • 23
    Zangwill SD, Ellis TM, Zlotocha J et al. The virtual crossmatch—A screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant 2006; 10: 3841.
  • 24
    McLaughlin K, Manns B, Nickerson P. The routine use of high-resolution immunological screening of recipients of primary deceased donor kidney allografts is cost-effective. Transplantation 2006; 81: 12781284.